CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
Open Access
- 15 March 2012
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 68 (9), 1267-1274
- https://doi.org/10.1007/s00228-012-1252-3
Abstract
Objectives Pantoprazole is metabolized by cytochrome P450 2 C19, which shows genetic polymorphism. The effect of CYP2C19 polymorphism on single-dose pharmacokinetics of oral pantoprazole in healthy volunteers was evaluated. Methods Pantoprazole pharmacokinetics was determined in 32 healthy volunteers after a 40-mg single oral dose of the drug. Results Carriers of CYP2C19*2/*2 (n = 2) were characterized by higher, starting from 3.5 h post dose, plasma concentrations of pantoprazole in comparison to wild-type (CYP2C19*1/*1, n = 6) volunteers. In subjects with CYP2C19*17/*17 genotype (n = 6) significantly lower plasma concentrations of the drug vs CYP2C19*1/*1 carriers, were observed from 3.0 h after oral pantoprazole administration. Carriers of CYP2C19*1/*17 (n = 6) and CYP2C19*2/*17 (n = 6) displayed concentration–time profiles comparable to wild-type subjects. CYP2C19*2/*2 volunteers showed a decrease in terminal elimination rate constant (λz) by 83.3%, prolongation of terminal half-life (t½) by 572%, a rise in area under the concentration–time curve (AUC) and mean residence time (MRT) by 506% and 259% respectively. Heterozygotes, i.e.. CYP2C19*1/*2 vs CYP2C19*1/*1 were characterized by higher AUC (4.38 ± 1.00 mg⋅h/L vs 3.00 ± 1.02 mg⋅h/L, p < 0.05) and Cmax (2.13 ± 0.42 mg/L vs 1.61 ± 0.35 mg/L, p < 0.05) respectively. A significant reduction in MRT (3.83 ± 0.82 h vs 2.73 ± 0.23 h, p < 0.05) in carriers of CYP2C19*17/*17 vs CYP2C19*1/*1 genotypes was observed. Population modeling confirmed the influence of *1/*2, *2/*2, and *17/*17 genotypes on the pharmacokinetics of pantoprazole. The lowest population oral clearance was assessed in the carriers of genotype *2/*2 (3.68 L/h) and the highest value in subjects with genotype *17/*17 (31.13 L/h). Conclusion These data suggest that CYP2C19 polymorphism is an important determinant of pantoprazole pharmacokinetics.Keywords
This publication has 21 references indexed in Scilit:
- Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential EffectPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2010
- Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent PlacementCell Metabolism, 2010
- A comparison of the acid‐inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphismAlimentary Pharmacology & Therapeutics, 2009
- Effect of CYP2C19 Genetic Polymorphisms on the Efficacy of Proton Pump Inhibitor‐Based Triple Therapy for Helicobacter pylori Eradication: A Meta‐AnalysisHelicobacter, 2008
- Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteersBritish Journal of Clinical Pharmacology, 2008
- Effect of CYP2C19 *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in CaucasiansBritish Journal of Clinical Pharmacology, 2008
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsCancer Cell, 2006
- PantoprazoleDrugs, 2003
- DEVELOPMENT OF A REVERSED-PHASE LIQUID CHROMATOGRAPHIC METHOD FOR THE ANALYSIS OF AMOXICILLIN, METRONIDAZOLE, AND PANTOPRAZOLE IN HUMAN PLASMA USING SOLID-PHASE EXTRACTIONJournal of Liquid Chromatography & Related Technologies, 2002
- Genetic polymorphism of S-mephenytoin hydroxylationPharmacology & Therapeutics, 1989